Unknown

Dataset Information

0

Targeting ?2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.


ABSTRACT: Von Hippel-Lindau (VHL), is a rare autosomal dominant inherited cancer in which the lack of VHL protein triggers the development of multisystemic tumors such us retinal hemangioblastomas (HB), CNS-HB, and clear cell renal cell carcinoma (ccRCC). ccRCC ranks third in terms of incidence and first in cause of death. Standard systemic therapies for VHL-ccRCC have shown limited response, with recurrent surgeries being the only effective treatment. Targeting of ?2-adrenergic receptor (ADRB) has shown therapeutic antitumor benefits on VHL-retinal HB (clinical trial) and VHL-CNS HB (in vitro). Therefore, the in vitro and in vivo antitumor benefits of propranolol (ADRB-1,2 antagonist) and ICI-118,551 (ADRB-2 antagonist) on VHL-/- ccRCC primary cultures and 786-O tumor cell lines have been addressed. Propranolol and ICI-118,551 activated apoptosis inhibited gene and protein expression of HIF-2?, CAIX, and VEGF, and impaired partially the nuclear internalization of HIF-2? and NF?B/p65. Moreover, propranolol and ICI-118,551 reduced tumor growth on two in vivo xenografts. Finally, ccRCC patients receiving propranolol as off-label treatment have shown a positive therapeutic response for two years on average. In summary, propranolol and ICI-118,551 have shown antitumor benefits in VHL-derived ccRCC, and since ccRCCs comprise 63% of the total RCCs, targeting ADRB2 becomes a promising drug for VHL and other non-VHL tumors.

SUBMITTER: Albinana V 

PROVIDER: S-EPMC7563408 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.

Albiñana Virginia V   Gallardo-Vara Eunate E   de Rojas-P Isabel I   Recio-Poveda Lucia L   Aguado Tania T   Canto-Cano Ana A   Aguirre Daniel T DT   Serra Marcelo M MM   González-Peramato Pilar P   Martínez-Piñeiro Luis L   Cuesta Angel M AM   Botella Luisa Maria LM  

Journal of clinical medicine 20200825 9


Von Hippel-Lindau (VHL), is a rare autosomal dominant inherited cancer in which the lack of VHL protein triggers the development of multisystemic tumors such us retinal hemangioblastomas (HB), CNS-HB, and clear cell renal cell carcinoma (ccRCC). ccRCC ranks third in terms of incidence and first in cause of death. Standard systemic therapies for VHL-ccRCC have shown limited response, with recurrent surgeries being the only effective treatment. Targeting of β2-adrenergic receptor (ADRB) has shown  ...[more]

Similar Datasets

| S-EPMC2629664 | biostudies-literature
| S-EPMC4918695 | biostudies-literature
| S-EPMC2837060 | biostudies-literature
| S-EPMC2970636 | biostudies-literature
| S-EPMC8353948 | biostudies-literature
| S-EPMC3361062 | biostudies-literature
| S-EPMC5323317 | biostudies-literature
| S-EPMC8486188 | biostudies-literature
| S-EPMC10863383 | biostudies-literature
| S-EPMC5541202 | biostudies-other